Deoxynucleotidyl Transferase (TdT) News and Research

RSS

New study reveals unique immune responses to SARS-CoV-2, Ebola and respiratory syncytial virus using B cell repertoire analysis

A new study has been published on the bioRxiv* preprint server, which takes a long-read repertoire amplification approach to better understand, compare and contrast B cell responses to emerging or endemic viruses.

23 Aug 2021

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

Conception plans miscarry with sperm DNA damage

Sperm with damaged DNA are more likely to cause spontaneous pregnancy loss, report researchers.

30 Jul 2012

First 'theranostic' agent for treatment of ALL

A team of researchers at Case Western Reserve University School of Medicine has developed the first "theranostic" agent for the treatment of acute lymphoblastic leukemia (ALL).

8 Mar 2012

OncoVista plans to advance reduced-toxicity targeted cancer treatments

OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity.

11 Mar 2011

Genetic variation in taste pathway genes associated with dental caries risk

Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.

23 Sep 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

REGENERX BIOPHARMACEUTICALS, INC. announced today that a university research team has published an article ahead of print in FASEB Journal, a high-impact scientific journal, describing novel biological properties of several Thymosin beta 4 (Tβ4) peptide fragments.

27 Feb 2010